1053. Association Between Serum 25-Hydroxyvitamin D Level and Type of Coccidioidal Infection
Session: Poster Abstract Session: Fungal Pathogenesis and Virulence
Saturday, October 22, 2011
Room: Poster Hall B1

Background:  Recent studies have demonstrated an essential role for vitamin D in innate immunity. Prior studies have shown serum 25(OH) vitamin D levels are inversely associated with the development of upper respiratory tract infections, and with a higher risk of active tuberculosis.  A possible association of low serum 25(OH) vitamin D levels and invasive fungal infections, such as coccidioidomycosis, has not previously been assessed. 

Methods:  We reviewed and analyzed the clinical and laboratory results of 88 patients evaluated for coccidioidomycosis excluding patients with a prior diagnosis of vitamin D deficiency or taking Vitamin D supplements.  All samples were tested for the presence of coccidioidal IgM and IgG antibodies by both immunodiffusion and complement fixation.  Serum 25(OH) vitamin D levels were performed by a centralized laboratory (ARUP, Salt Lake City, UT).


No statistically significant differences were found between negative controls, Coccidioides immune patients, those with primary coccidioidal pneumonia, or disseminated disease reagarding age, sex, or ethnicity.  Serum 25-OH Vitamin D levels were also not significantly different between groups (p=0.107).

Conclusion: Despite recent evidence demonstrating the essential role of vitamin D in other conditions dependent upon lymphocyte responsiveness and antigen presenting cells our results do not support vitamin D deficiency is a similar risk factor for coccidioidomycosis. 

Subject Category: M. Mycology including clinical and basic studies of fungal infections

George R. Thompson III, MD1, Derek Bays2, Rachel Pruitt2, Stuart Cohen, MD, FIDSA3 and Demosthenes Pappagianis, MD, PhD4, (1)Medical Microbiology and Immunology, University of California-Davis, Davis, CA, (2)University of California - Davis, Davis, CA, (3)University of California at Davis Medical Center, Sacramento, CA, (4)University of California School of Medicine, Davis, CA


G. R. Thompson III, Pfizer: Investigator, Research support

D. Bays, None

R. Pruitt, None

S. Cohen, None

D. Pappagianis, None

Findings in the abstracts are embargoed until 12:01 a.m. EST Thursday, Oct. 20 with the exception of research findings presented at IDSA press conferences.